Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gore

Showing results (51-60 of 157) with videos related to

Pageof 16
Sort By:
BMJ (Clinical Research Ed.)|May 2, 1998
Commentary: management of the patientS R Johnston, K Broadley, G Henson, et al.
Clinical and Experimental Dermatology|November 28, 2001
Clinico-pathological features of relapsing very thin melanomaL A Fearfield, A Rowe, N Francis, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Gut|August 1, 1990
Tumour necrosis factor, cholestatic jaundice, and chronic liver diseaseA Jones, P J Selby, C Viner, et al.
The British Journal of Dermatology|October 17, 2012
Second primary melanomas on treatment with vemurafenib: reply from the authorsL Fearfield, J A Newton-Bishop, R Sinha, et al.
British Journal of Cancer|November 1, 1989
Cisplatin/carboplatin cross-resistance in ovarian cancerM E Gore, I Fryatt, E Wiltshaw, et al.
The British Journal of Dermatology|August 24, 2012
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicitiesR Sinha, K Edmonds, J A Newton-Bishop, et al.
Lancet (London, England)|August 3, 1985
Disturbance of blood-brain barrier after bone-marrow transplantationJ P Sloane, K Y Lwin, M E Gore, et al.
The Journal of Pathology|June 1, 1995
The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinomaJ Salter, K A Maclennan, J Moore, et al.
British Journal of Cancer|February 1, 1990
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefitS Lakhani, P Selby, J M Bliss, et al.
Pageof 16

Showing results (51-60 of 157) with videos related to

Sort By:
Pageof 16
BMJ (Clinical Research Ed.)|May 2, 1998
Commentary: management of the patientS R Johnston, K Broadley, G Henson, et al.
Clinical and Experimental Dermatology|November 28, 2001
Clinico-pathological features of relapsing very thin melanomaL A Fearfield, A Rowe, N Francis, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Gut|August 1, 1990
Tumour necrosis factor, cholestatic jaundice, and chronic liver diseaseA Jones, P J Selby, C Viner, et al.
The British Journal of Dermatology|October 17, 2012
Second primary melanomas on treatment with vemurafenib: reply from the authorsL Fearfield, J A Newton-Bishop, R Sinha, et al.
British Journal of Cancer|November 1, 1989
Cisplatin/carboplatin cross-resistance in ovarian cancerM E Gore, I Fryatt, E Wiltshaw, et al.
The British Journal of Dermatology|August 24, 2012
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicitiesR Sinha, K Edmonds, J A Newton-Bishop, et al.
Lancet (London, England)|August 3, 1985
Disturbance of blood-brain barrier after bone-marrow transplantationJ P Sloane, K Y Lwin, M E Gore, et al.
The Journal of Pathology|June 1, 1995
The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinomaJ Salter, K A Maclennan, J Moore, et al.
British Journal of Cancer|February 1, 1990
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefitS Lakhani, P Selby, J M Bliss, et al.
Pageof 16